• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » TAVI: Strong results for heart valves from Edwards Lifesciences, Medtronic

TAVI: Strong results for heart valves from Edwards Lifesciences, Medtronic

March 16, 2015 By Brad Perriello

TAVI: Strong results for heart valves from Edwards Lifesciences, Medtronic

Transcatheter aortic valve implants once again took the spotlight at the annual meeting of the American College of Cardiology, with a spate of studies both confirming the long-term benefits of the replacement heart valves and showing that newer TAVI versions are even better.

The results position TAVI to become the standard of care for aortic valve stenosis, according to Leerink Partners analysts Danielle Antalffy.

“The key take-home message from ACC was that TAVI is rapidly advancing toward standard of care in not just high-risk and inoperable patients but also in the much larger intermediate-risk patient population – likely to support double-digit TAVI market growth for the foreseeable future," Antalffy wrote this morning in a note to investors.

Final 5-year data for Edwards Lifesciences‘ (NYSE:EW) market-leading Sapien device from the Partner trial, presented over the weekend at the ACC meeting in San Diego, showed its benefits and durability in both inoperable and high-risk groups.

After 5 years the inoperable cohort showed an all-cause mortality rate of 71.8%, compared with 93.6% for the TAVI control group, patients treated with open heart surgery. For the high-risk TAVI group, the 5-year mortality rate was 67.8%, compared with 62.4% for the surgical control arm.

"It’s remarkable that this 5-year data report continues to show equivalency between what was then a brand-new procedure with a 1st-generation TAVI device and the gold standard of surgery, which has been honed over 50 years of experience," Dr. Michael Mack, who presented the results at ACC, said in prepared remarks. "Just as we observed in the 5-year report from the Partner trial on outcomes in inoperable patients treated with Sapien, the high-risk patients also had durable valve performance. These data show that TAVI is an effective treatment for these patients."

Medtronic’s competing CoreValve device also did well, with 2-year results showing that TAVI patients fared better than the t surgical valve replacement control group. The data, also presented at ACC, not only showed that results seen at 1 year were sustained a year later, but that there were greater differences favoring CoreValve over open heart surgery.

The rate of all-cause mortality or major stroke at 2 years was 24.2% for CoreValve, versus 32.5% for surgery, a greater difference than 1-year rates of 16.2% and 22.5%. The difference in all-cause mortality alone and for all strokes in the trial of 750 high-risk patients also favored TAVI by a wider margin at 2 years. For all strokes, the rate after two years was 10.9% for CoreValve versus 16.6% for surgery.

"This data is strong enough that it should change our guidelines in the increased risk surgical population where TAVR is not just an alternative to surgery, but it should be the preferred option," said lead investigator Dr. Michael Reardon, noting that It had been believed that TAVI would have a hard time competing with surgical results.

"We did really good surgery and at 2 years there was a survival advantage [for TAVI] that was highly statistically significant," Reardon said. "When you look at the way the field is going, for me as a cardiac surgeon it may not be that great, but for our patients it’s really groundbreaking."

Next-generation devices even better

Results for the 3rd-generation Sapien 3 from Edwards showed very low mortality and stroke rates at 30 days, with a 2.2% mortality rate in high-risk patients and a 1.1% death rate among intermediate-risk patients. The rate for all strokes at 30 days was 1.5% for high-risk patients and 2.6% for the intermediate-risk group. The disabling stroke rates were 0.86% and 1%.

"The numbers that we’re seeing are truly phenomenal," said co-lead investigator Dr. Susheel Kodali. "This is a sick population."

The results demonstrated a clear improvement over those seen in prior studies of two earlier Sapien iterations and compared favorably to historical complication expectations for surgical valve replacement, Kodali said. The mortality rate for high-risk patients in a trial of the original Sapien was more than 5%, he explained.

The Sapien 3 features a smaller catheter to deliver the valve to the heart than its predecessors, and an improved design aimed at minimizing valve leakage. It has been in use in Europe for high risk and inoperable patients since early 2014. Edwards is hoping to gain U.S. approval in early 2016.

The study involved 583 high-risk and 1,076 intermediate-risk patients with an average age of about 82.

The combined rate of moderate or severe valve leakage was under 4%. "In terms of reducing significant perivalvular leak, the rates are extremely low," said Kodali, director of the Heart Valve Center at Columbia New York Presbyterian Hospital.

In coming years, Kodali said, he envisions TAVI will no longer be viewed as a secondary option. "The conversation will be who’s going to be getting surgery in the era of TAVI."

Thirty-day results for Medtronic’s next-generation TAVI offering, the CoreValve Evolut R, were also extremely promising. The 60-patient Evolut R trial showed no incidents of all-cause mortality or stroke in a high- and extreme-risk patients, Medtronic said.

"Initial clinical experience with the Evolut R system is remarkable and ushers in a new era of TAVI technology that provides increased confidence with recapturability, excellent procedural results, and impressive clinical outcomes," study investigator Dr. Ian Meredith said in prepared remarks. "The 14 French-equivalent delivery system allowed transfemoral access for most patients and the recapturable technology enabled implanters to optimize valve placement for improved annular sealing and reduced conduction disturbances without compromise on mortality or stroke."

Material from Reuters was used in this report.

Filed Under: News Well, Replacement Heart Valves Tagged With: American College of Cardiology, Clinical Trials, Edwards Lifesciences

In case you missed it

  • Report: Dexcom in talks to acquire Insulet
  • Henry Schein investors push back on executive pay
  • Alcon to pay $60M to acquire Kala Pharmaceuticals’ dry eye treatment
  • Creo Medical inks collaboration agreement with Intuitive
  • MedTrace Pharma moves forward on 15 O-water imaging tech
  • HistoSonics, GE Healthcare agree to integrate ultrasound into sonic beam liver therapy
  • Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children
  • Zimmer Biomet narrowly avoids shareholder rebuke on executive pay
  • FDA says Philips ventilator recall produced over 21,000 device reports, 124 deaths
  • Boston Scientific’s Acurate Neo2 valve performs well in studies
  • MicroTransponder reports first commercial implantation of its stroke rehab neurostim system
  • Ambu replaces CEO with new leadership
  • Moderna’s first bivalent COVID-19 vaccine booster candidate shows promise
  • AdvaMed joins Biden’s Joint Supply Chain Resilience Working Group
  • FDA clears Accelus’ Toro-L interbody fusion system
  • Teleflex’s UroLift cleared in China to treat BPH
  • Globus Medical announces first surgeries with Excelsius3D

RSS From Medical Design & Outsourcing

  • Henry Schein investors push back on executive pay
    Nearly half of Henry Schein (Nasdaq:HSIC) shareholders who voted at this month’s annual meeting voted against the company’s pay packages for top executives, according to a new SEC filing. About 48.5% of voting shareholders voted against the company’s executive pay plan in what’s known as the Say-on-Pay vote, according to vote results of the May… […]
  • Creo Medical inks collaboration agreement with Intuitive
    Creo Medical Group (LON: CREO) announced today that it has signed a multi-year collaboration agreement with Intuitive to make certain Creo surgical technologies compatible with the surgical robotic giant’s systems. The London exchange reacted by sending CREO shares up more than 4% to 100 pence apiece by the close of trading today. As of midday… […]
  • MedTrace Pharma moves forward on 15 O-water imaging tech
    MedTrace Pharma announced the first person scanned in its Rapid-Water-Flow Phase 3 clinical trial, further testing its tech to bring 15 O-water to imaging. The first subject scan took place at Aarhus University Hospital in Denmark, using 15 O-water produced, dosed and injected through MedTrace’s P3 automated delivery system. The clinical trial aims to evaluate… […]
  • Zimmer Biomet narrowly avoids shareholder rebuke on executive pay
    An unusually large share of Zimmer Biomet (NYSE:ZBH) investors voted against the orthopedics company’s pay packages for top executives at the annual shareholder meeting. About 54% of voting shareholders supported the pay packages of the company’s five top-paid executives at the May 13 meeting, according to results filed with the SEC yesterday. In 2021, nearly 93%… […]
  • BD, Mitsubishi Gas Chemical partner on better materials for plastic syringes
    BD (NYSE:BDX) announced that it partnered with Mitsubishi Gas Chemical Company on applying new technology to pre-fillable syringes. MGC develops the Oxycapt technology designed to integrate the best of plastic and glass for plastic syringes. BD and Tokyo-based MGC will work together to apply Oxycapt technology to the next generation of pre-fillable syringes (PFS) for advanced… […]
  • Ambu replaces CEO with new leadership
    Ambu today said it has hired board member Britt Meelby Jensen to replace CEO Juan Jose Gonzalez, effective tomorrow. “Since Juan Jose Gonzalez joined as CEO in 2019, Ambu has made good progress and achieved important milestones on the strategic transformation into the world’s largest single-use endoscopy company,” Ambu Chair Jørgen Jensen said in a… […]
  • AdvaMed joins Biden’s Joint Supply Chain Resilience Working Group
    AdvaMed executive Abby Pratt has joined the executive committee for the Biden administration’s Joint Supply Chain Resilience Working Group, the medtech industry association said today. The working group’s members from government and industry will assist with implementation of the National Strategy for a Resilient Public Health Supply Chain. Pratt oversees supply chain issues as SVP… […]
  • Toray develops new stretchable film for medical devices
    Toray Industries has a new stretchable film based on its proprietary polymer Reactis technology, with potential applications that include robotics and biological and industrial sensors. Tokyo-based Toray said it shipped samples to customers and plans research and development efforts to commercialize the new grade of film. “Recent years have increased the potential for developing stretchable… […]
  • Google Health hires FDA’s chief digital health officer
    Former FDA Chief Digital Health Officer of Global Strategy and Innovation Bakul Patel has started a new job with Google after 13 years with the regulatory agency. Patel became senior director, global digital health strategy and regulatory for Google Health earlier this month, he said on LinkedIn. Patel recounted highlights of his “incredible journey since… […]
  • Expect more heart and lung failure years after COVID, Abbott’s heart failure CMO says
    Two years into the COVID-19 pandemic, we know more than ever about the SARS-CoV-2 virus and how quickly it moves to ravage the human body. What remains to be seen is how the virus — and perhaps more importantly, our immune system’s response to it — will affect the health of people long after infection,… […]
  • FDA moves forward with Voluntary Improvement Program to bolster medical device quality
    Kathryn Burke, Emergo Group The U.S. Food and Drug Administration has issued new draft guidance to establish a full-blown voluntary program for improving quality-related processes in medical device manufacturing following promising results of a pilot program. The FDA guidance stems from a pilot undertaken by the agency along with the Medical Device Innovation Consortium (MDIC) in 2018.… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS